Recent news articles discuss how NextBio scales technology to handle genomics data
As genomic data makes its way from specialized laboratories into routine healthcare evaluations, it is perhaps appropriate that announcements of the latest sequencers were made at the Consumer Electronics Show in Las Vegas rather than the upcoming Advances in Genome Biology and Technology conference.
New machines from Illumina and Life Technologies only strengthen the idea that 2012 is, in fact, the year of the $1000 genome. Led by a trickle of individual success stories, genome sequencing appears to be on the verge of altering the clinical landscape. While the FDA and regulatory bodies resolve the consumer issues of reimbursement and regulation crucial to patients, here at NextBio we tackle an intermediate problem: Making sense of the data. Read more…
